KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Income from Continuing Operations (2019 - 2025)

Royalty Pharma's Income from Continuing Operations history spans 7 years, with the latest figure at 355913000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 6.45% year-over-year to 355913000.0; the TTM value through Dec 2025 reached 1324192000.0, changed 0.5%, while the annual FY2025 figure was 1324192000.0, 0.5% changed from the prior year.
  • Income from Continuing Operations for Q4 2025 was 355913000.0 at Royalty Pharma, down from 444211000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 806755000.0 in Q2 2021 and bottomed at 610030000.0 in Q4 2022.
  • The 5-year median for Income from Continuing Operations is 278073500.0 (2021), against an average of 291317900.0.
  • The largest annual shift saw Income from Continuing Operations crashed 1236.61% in 2022 before it surged 10243.53% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 53671000.0 in 2021, then plummeted by 1236.61% to 610030000.0 in 2022, then surged by 217.63% to 717586000.0 in 2023, then crashed by 53.41% to 334351000.0 in 2024, then rose by 6.45% to 355913000.0 in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Income from Continuing Operations are 355913000.0 (Q4 2025), 444211000.0 (Q3 2025), and 90635000.0 (Q2 2025).